Methenamine Hippurate Eql Pharma

Methenamine Hippurate, the active ingredient in Methenamine Hippurate Eql Pharma, is a urinary antiseptic presented as an oral dosage form for oral use. It is employed to prevent recurrent urinary tract infections by delivering antibacterial activity within acidic urine in adult patients and can be used as a prophylactic agent in individuals with a history of urinary infections.

GNH USA supplies Methenamine Hippurate Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and other healthcare institutions.

Methenamine Hippurate is a urinary antiseptic used for prophylaxis of urinary tract infections.

Prevention of recurrent urinary tract infections: reduces the frequency of infection episodes in susceptible adults. Urinary antiseptic: provides antibacterial activity in acidic urine to suppress bacterial growth. Catheter‑associated urinary infection prophylaxis: helps lower infection risk in patients with indwelling catheters. Post‑operative urinary infection prevention: used to minimize infection risk after urological surgeries. Prophylaxis in patients with neurogenic bladder: reduces infection incidence in individuals with impaired bladder emptying.

Methenamine Hippurate may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset. - Vomiting: occasional episodes. - Abdominal discomfort: cramping or pain. - Dysuria: burning sensation during urination. - Headache: mild.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with hives, swelling, and breathing difficulty. - Hemolytic anemia: destruction of red blood cells leading to fatigue and jaundice. - Methemoglobinemia: elevated methemoglobin causing cyanosis and shortness of breath. - Stevens‑Johnson syndrome: severe skin rash and blistering.

When prescribing Methenamine Hippurate, several safety considerations should be observed.

Renal function assessment: evaluate kidney function before initiating therapy. Urine pH requirement: effectiveness requires acidic urine (pH < 6); alkalinizing agents may diminish benefit. Pregnancy safety: avoid use unless clearly needed, as safety data are limited. Concomitant alkalinizing agents: avoid sodium bicarbonate or citrate supplements that raise urine pH. History of hypersensitivity: discontinue if allergic reactions occur. Store at room temperature: keep in original container, protect from moisture and heat.

Methenamine Hippurate can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Alkalinizing agents (e.g., sodium bicarbonate, potassium citrate): raise urine pH and markedly reduce drug activation. - Formaldehyde‑releasing antiseptics: additive toxicity may increase risk of mucosal irritation.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect; monitor INR. - Diuretics: may alter urine concentration and affect drug hydrolysis. - Antacids: can affect absorption of the oral formulation; monitor therapeutic response.